Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail.
about
Hsp90 activator Aha1 drives production of pathological tau aggregates.Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors.Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects.Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development.
P2860
Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Diverging Novobiocin Anti-Canc ...... odification of the Amide Tail.
@en
Diverging Novobiocin Anti-Canc ...... odification of the Amide Tail.
@nl
type
label
Diverging Novobiocin Anti-Canc ...... odification of the Amide Tail.
@en
Diverging Novobiocin Anti-Canc ...... odification of the Amide Tail.
@nl
prefLabel
Diverging Novobiocin Anti-Canc ...... odification of the Amide Tail.
@en
Diverging Novobiocin Anti-Canc ...... odification of the Amide Tail.
@nl
P2093
P2860
P1476
Diverging Novobiocin Anti-Canc ...... odification of the Amide Tail.
@en
P2093
Brian S J Blagg
Gaurav Garg
Jiacheng Ma
Mercy Anyika
Nolan T McPherson
Rick T Dobrowsky
Suman Ghosh
P2860
P304
P356
10.1021/ACSMEDCHEMLETT.6B00224
P577
2016-07-05T00:00:00Z